Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

NCT02750618 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
13
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Kyowa Kirin, Inc.